News headlines about OncoSec Medical (NASDAQ:ONCS) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OncoSec Medical earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.2778227950852 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern’s scoring:
- OncoSec Medical Incorporated (ONCS) stock’s Technical story – Wall Street Morning (wallstreetmorning.com)
- OncoSec Medical Incorporated (ONCS) clocked 32.65% higher to SMA-200 – The Stocks News (press release) (thestocksnews.com)
- Early Moves to Watch – OncoSec Medical Incorporated (NASDAQ: ONCS) – Alpha Beta Stock (alphabetastock.com)
- Is The Stock Ready to Shift Trend? – OncoSec Medical Incorporated (NASDAQ: ONCS) – The Investor Guide (wallstreetnews24.com)
- Here’s What to Focus on – OncoSec Medical Incorporated (NASDAQ: ONCS) – Stocks Pen (stockspen.com)
Several brokerages have recently issued reports on ONCS. Piper Jaffray Companies began coverage on shares of OncoSec Medical in a research note on Friday, February 9th. They issued an “overweight” rating and a $4.00 target price on the stock. HC Wainwright set a $6.00 target price on shares of OncoSec Medical and gave the stock a “buy” rating in a research note on Friday, January 19th. Maxim Group set a $5.00 target price on shares of OncoSec Medical and gave the stock a “buy” rating in a research note on Thursday, December 14th. Finally, ValuEngine downgraded shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $5.00.
In related news, CEO Daniel J. O’connor acquired 16,667 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was purchased at an average cost of $1.50 per share, with a total value of $25,000.50. Following the completion of the acquisition, the chief executive officer now directly owns 16,667 shares of the company’s stock, valued at $25,000.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.50% of the stock is owned by insiders.
WARNING: This piece of content was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3228117/oncosec-medical-oncs-receives-daily-news-sentiment-score-of-0-05.html.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.